Nanexa has entered into a global exclusive license and collaboration agreement with Novo for the use of the PharmaShell technology platform for certain peptide-based drugs targeting obesity, type 2 diabetes and other cardiometabolic indications.

The Helsinki-based company has closed a EUR 30 million Series A round led by Hadean Ventures to take its lead candidate, a TrkB potentiator designed to deliver the benefits of psychedelics without the hallucinations, into clinical trials for major depressive disorder.

The Oslo-based radiopharmaceutical company has raised NOK 148.5 million in a private placement and retail offering to complete its Phase 2 ovarian cancer trial and prepare for Phase 3.

The company is to separate its Operating Room Solutions (ORS) and Gloves businesses into a new standalone company, provisionally named ‘Mölnlycke Surgical’, while Wound Care and Antiseptics continue as Mölnlycke.

RaySearch Laboratories and US-based Accuray have entered a definitive agreement to expand their collaboration on online adaptive radiation therapy, with Accuray committing to purchase RayStation software licences worth USD 8 million.

Glycorex Transplantation has agreed a distribution deal with Grupo VIDA for its Glycosorb ABO technology in Brazil, as part of the Swedish medtech company’s continued market expansion.

Swedish biotech company MucoShield is developing a locally administered, fast-acting treatment to protect the oral mucosa during chemotherapy and prevent severe chemotherapy-induced oral mucositis, one of the most painful and debilitating side effects of cancer treatment.

BioArctic’s Alzheimer’s drug Leqembi is now available at a private clinic in Stockholm, where the first patient in Sweden to receive the drug outside a clinical trial started treatment on September 22. This comes five months after the NT Council advised Sweden’s regions against using it.

Elicera Therapeutics has received approval from the Swedish Medical Products Agency (Läkemedelsverket) to move its CARMA study of the CAR T-cell therapy ELC-301 in B-cell lymphoma into Phase IIa.

SciLifeLab is increasing its space on Campus Solna by more than 9,000m². Property owner Akademiska Hus is investing approximately SEK 230 million in an extensive renovation that will give the research center more modern laboratories, flexible workspaces, and new facilities for meetings and training.

Cancer incidence among adults under 50 increased for 12 of 18 cancer sites in the Nordic countries between 2003 and 2022, according to a registry study published in The Lancet Regional Health – Europe. Researchers including scientists from Karolinska Institutet analysed more than 2.2 million cases from seven Nordic countries covering nearly 28 million people.

Patients who had high-risk polyps removed and waited five years for their first follow-up colonoscopy had a colorectal cancer risk similar to those examined after three years, according to two studies in the New England Journal of Medicine involving Karolinska Institutet (KI) researchers.